Wipfli Financial Advisors’s Krystal Biotech KRYS Stock Holding History

Wipfli Financial Advisors’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$7K	Buy	+106	New	+$7.66K	﹤0.01%	1970

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Wipfli Financial Advisors's KRYS Position: Q3 2022 in Review

Wipfli Financial Advisors opened a new position in Krystal Biotech (KRYS) in Q3 2022: 106 shares worth $7K. The stake represents ﹤0.01% of the portfolio and ranks #1970 among its holdings.

148 funds tracked by Wall St. Rank hold KRYS as of Q3 2022.

Wipfli Financial Advisors held 106 shares of Krystal Biotech worth $7K as of Q3 2022.
Krystal Biotech was a new Wipfli Financial Advisors position in Q3 2022.
Krystal Biotech made up ﹤0.01% of Wipfli Financial Advisors's portfolio in Q3 2022, its #1970 holding.
148 funds tracked by Wall St. Rank held Krystal Biotech as of Q3 2022.

Based on Wipfli Financial Advisors's 13F filing for Q3 2022, filed 26 Oct 2022.